Diagnosing melanoma: the method matters

• 1 Melanoma Institute Australia, Sydney, NSW
• 2 Sydney Medical School, University of Sydney, Sydney, NSW
• 3 Royal Prince Alfred Hospital, Sydney, NSW

---

• 1. de Menezes SL, Kelly JW, Wolfe R, et al. The increasing use of shave biopsy for diagnosing invasive melanoma in Australia. Med J Aust 2019; 211: 213–218.
• 2. Gershenwald JE, Scolyer RA, Hess KR, et al; American Joint Committee on Cancer Melanoma Expert Panel, International Melanoma Database and Discovery Platform. Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 472–492.
• 3. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF‐mutated melanoma. N Engl J Med 2017; 377: 1813–1823.
• 4. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378: 1789–1801.
• 5. Weber J, Mandala M, Del Vecchio M, et al. American Joint Committee on Cancer Melanoma Expert Panel, International Melanoma Database and Discovery Platform. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824–1835.
• 6. Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Updated Apr 2019. https://wiki.cancer.org.au/australiawiki/index.php?oldid=201397 (viewed May 2019).
• 7. Ng JC, Swain S, Dowling JP, et al. The impact of partial biopsy on histopathologic diagnosis of cutaneous melanoma: experience of an Australian tertiary referral service. Arch Dermatol 2010; 146: 234–239.
• 8. Egnatios GL, Dueck AC, Macdonald JB, et al. The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanoma. Am J Surg 2011; 202: 771–777.
• 9. Hieken TJ, Hernández‐Irizarry R, Boll JM, Jones Coleman JE. Accuracy of diagnostic biopsy for cutaneous melanoma: implications for surgical oncologists. Int J Surg Oncol 2013; 2013: 196493.
• 10. Lowe M, Hill N, Page A, Delman KA. The impact of shave biopsy on the management of patients with thin melanomas. Am Surg 2011; 77: 1050–1053.
• 11. Mills JK, White I, Diggs B, et al. Effect of biopsy type on outcomes in the treatment of primary cutaneous melanoma. Am J Surg 2013; 205: 585–590.
• 12. Mir M, Chan CS, Khan F, at al. The rate of melanoma transection with various biopsy techniques and the influence of tumor transection on patient survival. J Am Acad Dermatol 2013; 68: 452–458.
• 13. Zager JS, Hochwald SN, Marzban SS, et al. Shave biopsy is a safe and accurate method for the initial evaluation of melanoma. J Am Coll Surg 2011; 212: 454–460.
• 14. Kaiser S, Vassell R, Pinckney RG, at al. Clinical impact of biopsy method on the quality of surgical management in melanoma. J Surg Oncol 2014; 109: 775–779.
• 15. Saco M, Thigpen J. A retrospective comparison between preoperative and postoperative Breslow depth in primary cutaneous melanoma: how preoperative shave biopsies affect surgical management. J Drugs Dermatol 2014; 13: 531–536.
• 16. Moore P, Hundley J, Levine EA, at al. Does shave biopsy accurately predict the final Breslow depth of primary cutaneous melanoma? Am Surg 2009; 75: 369–373.
• 17. Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel‐node metastasis in melanoma. N Engl J Med 2017; 376: 2211–2222.
• 18. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma of the skin. In: Amin MB, Edge SB, Greene FL, editors. AJCC cancer staging manual. Cham: Springer International, 2017; pp. 563–585.
• 19. Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018; 25: 2105–2110.
• 20. Molenkamp BG, Sluijter BJ, Oosterhof B, at al. Non‐radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 2007; 14: 1424–1430.
• 21. Martin RC, Scoggins CR, Ross MI, et al. Is incisional biopsy of melanoma harmful? Am J Surg 2005; 190: 913–917.